<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1810234357
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1980
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEXOTANIL TAB. 3MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BROMAZEPAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Delpharm Milano S.r.l" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Delpharm Milano S.r.l
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CHEPLAPHARM Arzneimittel GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05BA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Pharmaceutical form<br />Lexotanil 3mg Tablet is light-red scored tablet,<br />3 mg bromazepam<br />- Therapeutic indications<br />Lexotanil is used for the treatment of emotional<br />disorders: anxiety and tension states, as adjuvant<br />therapy for anxiety in depression, nervous<br />tension, restlessness, and anxiety- and tensionrelated<br />insomnia.<br />Lexotanil can also be used for the treatment of<br />functional or psychosomatic impairments of<br />various organs caused or exacerbated by anxiety<br />and tension, and possibly as an adjuvant to<br />treatment of underlying disease of the<br />- cardiovascular and respiratory systems (e.g.<br />pseudoangina, precordial anxiety, tachycardia,<br />hypertension of emotional origin, dyspnea,<br />hyperventilation);<br />- gastrointestinal tract (e.g. adjuvant treatment<br />of irritable bowel syndrome, ulcerative colitis,<br />epigastric pain, spasm, abdominal distension,<br />diarrhea);<br />- urogenital system (e.g. irritable bladder,<br />urinary frequency, adjuvant treatment of<br />dysmenorrhea);<br />- other psychosomatic disorders (e.g.<br />adjuvant treatment of psychogenic headache,<br />psychogenic dermatoses).<br />Lexotanil is also suitable for treatment of<br />anxiety and tension states due to chronic<br />organic disease and as an adjuvant to<br />psychotherapy in psychoneuroses.<br />You must talk to a doctor if you do not feel better<br />or if you feel worse</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lexotanil Do not use Lexotanil:<br />- Lexotanil is contraindicated in patients with<br />hypersensitivity to benzodiazepines or any of<br />the excipients, severe respiratory<br />insufficiency, sleep apnea syndrome,<br />myasthenia gravis or severe hepatic<br />impairment (benzodiazepines may exacerbate<br />hepatic encephalopathy).<br />- Patients known or suspected to be dependent<br />on CNS depressants, including alcohol, must<br />not take benzodiazepines.<br />- if you are allergic to bromazepam or any of<br />the other ingredients of this medicine (listed<br />in section 6).<br />Tell your healthcare provider about all the<br />medicines you take, including prescription<br />and over-the-counter medicines, vitamins, and<br />herbal supplements.<br />General precautions<br />Concomitant use of alcohol/CNS depressants<br />The concomitant use of Lexotanil with alcohol<br />and/or CNS depressants should be avoided. Such<br />concomitant use can potentially intensify the<br />clinical action of Lexotanil, possibly with heavy<br />sedation and clinically relevant respiratory<br />and/or cardiovascular depression, which may<br />result in coma or death (see Interactions and<br />Overdose).<br />Lexotanil should be used with extreme caution<br />by patients in whom abuse of alcohol, medicinal<br />products, or illegal drugs has previously been<br />diagnosed.<br />Tolerance<br />Repeated use of Lexotanil for long periods can<br />lead to a reduction in the response to the action<br />of benzodiazepines.<br />Lexotanil tablets contain lactose. Patients with<br />rare hereditary galactose intolerance, lactase<br />deficiency, or glucose-galactose malabsorption<br />should not take Lexotanil tablets.<br />Impaired hepatic function<br />Benzodiazepines&nbsp;may play a contributory role in<br />precipitating episodes of hepatic encephalopathy<br />in patients with severe hepatic impairment<br />(see &ldquo;Contraindications&rdquo;). Particular caution is<br />required when administering Lexotanil to patients<br />with mild to moderate hepatic impairment.<br />Psychiatric and &ldquo;paradoxical&rdquo; reactions<br />Paradoxical reactions such as restlessness,<br />agitation, irritability, aggressiveness, anxiety,<br />delusion, fits of rage, nightmares, hallucinations,<br />psychosis, inappropriate behavior and other<br />adverse behavioral effects are known to occur<br />with the use of benzodiazepines. If such reactions<br />occur, use of the drug should be discontinued.<br />They are more likely to occur in children and<br />elderly patients than in other patients.<br />Elderly patients<br />The pharmacological effects of benzodiazepines<br />appear to be greater in elderly patients than<br />in younger patients, even at similar plasma<br />concentrations, possibly because of age-related<br />changes in drug-receptor interactions, postreceptor<br />mechanisms and organ function. Dose<br />reduction is recommended in patients over 50<br />years old.<br />Lexotanil with foods or drinks<br />While being treated with Lexotanil tablets, avoid<br />alcoholic beverages. Lexotanil tablets should be<br />swallowed with water or juice.<br />Pregnancy<br />Lexotanil should not be used during pregnancy</p><p>unless it is clearly necessary and there is no safer<br />alternative available.<br />If the drug is prescribed to a woman of childbearing<br />age, she should be advised to tell<br />her doctor if she plans to become or suspects<br />that she is pregnant, so that treatment may be<br />discontinued.<br />The safety of bromazepam in pregnant women<br />has not been established.<br />Lactation<br />As benzodiazepines pass into breast milk,<br />Lexotanil should not be taken by nursing mothers<br />or else breastfeeding should be discontinued.<br />Effects on ability to drive and use machines<br />As a consequence of the action and possible side<br />effects of the drug, the ability to drive, operate<br />machinery or undertake any other hazardous<br />activities may be impaired. Patients should<br />therefore abstain from such activities entirely or<br />at the very least for the first few days of treatment.<br />The decision in each individual case must be<br />made by the doctor in charge of the patient&rsquo;s<br />treatment on the basis of individual reaction and<br />the administered dose. The patient must also be<br />warned to abstain from alcohol while on the drug,<br />as this combination can potentiate the undesirable<br />effects of both substances.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Always use this medicine exactly as your<br />doctor or pharmacist has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />- The recommended dose is:<br />Average dose for outpatient treatment: 1.5 &ndash; 3 mg<br />up to three times daily.<br />In severe cases, especially for inpatients: 6 &ndash; 12<br />mg two to three times daily.<br />The doses indicated represent general guidelines<br />and must be individually tailored in each case.<br />Treatment of outpatients should begin with low<br />doses, which should be gradually titrated to the<br />optimum level.<br />- Duration of treatment<br />The duration of treatment should be as short<br />as possible. The patient&rsquo;s condition should be<br />reassessed at regular intervals and the need for<br />continuation of treatment determined, especially<br />when the patient&rsquo;s symptoms have resolved. As a<br />general rule, the total duration of treatment should<br />not exceed 8 &ndash; 12 weeks, including a tapering-off<br />period. In certain cases, treatment may need to be<br />continued beyond the maximum recommended<br />duration, but only after careful reassessment of<br />the patient&rsquo;s condition and the indication.<br />Patients should be examined regularly at the start<br />of treatment in order to minimize the dose and/or<br />frequency of administration and to avoid the risk<br />of overdose of the product due to accumulation.<br />At the outset it may be useful to inform the patient<br />that the duration of treatment will be for a limited<br />time only and that the dose will be gradually<br />reduced at the end of the treatment period. It is<br />important for the patient to be aware that rebound<br />effects and withdrawal symptoms may occur<br />when treatment is discontinued.<br />- Special dosage instructions:<br />Use in pediatric patients<br />As with other benzodiazepines, Lexotanil should<br />only be given to children and adolescents after<br />careful consideration of the relative risks and</p><p>benefits. If treatment with Lexotanil is considered<br />by a doctor to be indicated, the dose should be<br />adjusted to the child&rsquo;s lower body weight.<br />Use in elderly patients<br />Elderly patients require lower doses due to<br />potentially increased sensitivity and different<br />pharmacokinetics.<br />Impaired hepatic function<br />Patients with severe hepatic impairment should<br />not be treated with Lexotanil tablets. Patients<br />with mild or moderate hepatic impairment should<br />receive the lowest possible dose.<br />If you use more Lexotanil tablets than you<br />should:<br />Overdosage with benzodiazepines commonly<br />leads to stupor, ataxia, dysarthria, and nystagmus.<br />Although overdosage with Lexotanil is rarely<br />life-threatening when the product has been<br />taken on its own, it can lead to areflexia, apnea,<br />hypotension, cardiorespiratory depression, and<br />coma. If coma develops, it generally lasts only a<br />few hours, but can sometimes be protracted and<br />cyclic, particularly in the elderly. Respiratory<br />depression caused by benzodiazepines is more<br />severe in patients with respiratory illnesses.<br />Benzodiazepines potentiate the effects of other<br />CNS depressants, including alcohol.<br />Treatment<br />Monitor the&nbsp;patient&rsquo;s vital functions and<br />instigate whatever supportive measures are<br />indicated by his/her clinical state. Patients may,<br />in particular, require symptomatic treatment of<br />cardiorespiratory or CNS effects.<br />Further absorption should be prevented by<br />appropriate means, e.g. by treatment with activated<br />charcoal within 1&ndash;2 h. In drowsy patients, airway<br />protection is essential if activated charcoal is<br />administered. If more than one substance has<br />been ingested, gastric lavage may be considered,<br />but is not a routine countermeasure.<br />In patients with serious CNS depression,<br />administration of the benzodiazepine antagonist<br />flumazenil (Anexate&reg;) should be considered. This<br />product must, however, be administered under<br />close supervision and, because it only has a short<br />half-life (about one hour), patients administered<br />flumazenil must be kept under supervision once<br />its effects have worn off. Flumazenil must be<br />used with extreme caution after ingestion of<br />substances that lower the seizure threshold (e.g.<br />tricyclic antidepressants). For further information<br />on the correct use of flumazenil (Anexate&reg;), refer<br />to the prescribing information for the product.<br />If you forget to take Lexotanil tablets:<br />Do not take a double dose to make up for a<br />forgotten tablet. If you stop taking Lexotanil<br />tablets:<br />Withdrawal<br />Once physical dependence has developed,<br />discontinuation of treatment will be accompanied<br />by withdrawal symptoms. These may comprise<br />headache, diarrhea, muscle pain, extreme anxiety,<br />tension, restlessness, confusion and irritability. In<br />severe cases the following symptoms may occur:<br />derealisation, depersonalisation, hyperacusis,<br />numbness and tingling of extremities,<br />hypersensitivity to light, noise and physical&nbsp;contact, hallucinations or convulsions.<br />Withdrawal symptoms may also occur when<br />switching from one benzodiazepine to another<br />drug in the same class with a substantially shorter<br />elimination half-life.<br />Depending on the duration of action of the</p><p>substance, the onset of withdrawal symptoms can<br />vary from a few hours to a week or more after<br />discontinuation of treatment.<br />If you have any further questions on the use of<br />this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side<br />effects, although not everybody gets them.<br />Post-marketing experience<br />During treatment with bromazepam, the following<br />adverse effects can be expected to occur with<br />the greatest frequency: sedation, dizziness,<br />drowsiness, hypotension, poor concentration and<br />slow reactions. There have been frequent reports<br />of falls and fractures in benzodiazepine users.<br />The risk is increased in those taking concomitant<br />sedatives (including alcoholic beverages) and in<br />the elderly.<br />Psychiatric disorders<br />Confusional state, disorientation, emotional and<br />mood disturbances. These effects occur primarily<br />at the start of treatment and generally disappear<br />with continued use.<br />Pre-existing depression may be unmasked during<br />treatment with benzodiazepines.<br />Paradoxical reactions such as restlessness,<br />agitation, irritability, aggressiveness, delusion,<br />fits of rage, nightmares, hallucinations, psychosis,<br />inappropriate behavior, nervousness, anxiety,<br />abnormal dreams, hyperactivity and other<br />adverse behavioral effects are known to occur.<br />Such reactions are more common in children and<br />elderly patients than in other patients.<br />Nervous system disorders<br />Common: Fatigue, drowsiness, headache, poor<br />concentration, dizziness, slow reactions.<br />Rare: Ataxia, anterograde amnesia.<br />These effects occur primarily at the start of treatment<br />and generally disappear with continued use.<br />Anterograde amnesia may occur at therapeutic<br />doses, with the risk increasing at higher doses.<br />This means that things may happen (usually a few<br />hours) after taking the medication that the patient<br />cannot later remember.</p><p>Eye disorders<br />Double vision<br />This effect occurs primarily at the start of treatment<br />and generally disappears with continued use.<br />Ear and labyrinth disorders<br />Common: Dizziness<br />This effect occurs primarily at the start of treatment<br />and generally disappears with continued use.<br />Cardiac disorders<br />Heart failure, including cardiac arrest.<br />Respiratory, thoracic and mediastinal disorders<br />Respiratory depression.<br />Gastrointestinal disorders<br />Uncommon: Gastrointestinal disturbances<br />Rare: Nausea, dry mouth, increased appetite.<br />Skin and subcutaneous tissue disorders<br />Uncommon: Dermatological reactions</p><p>Musculoskeletal and connective tissue disorders<br />Rare: Muscle weakness<br />This effect occurs primarily at the start of treatment<br />and generally disappears with continued use.<br />Reproductive system and breast disorders<br />Uncommon: Changes in libido<br />Dependence<br />Long-term use (even at therapeutic doses) can<br />lead to physical and psychological dependence:<br />withdrawal symptoms or rebound effects may<br />occur when the drug is discontinued (see Warnings<br />and precautions). Abuse of benzodiazepines is<br />more common in multiple substance use.<br />If you get any side effects, talk to your doctor,<br />pharmacist or nurse. This includes any possible<br />side effects not listed in this leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of<br />children.<br />- Do not use this medicine after the expiry date<br />which is stated on the carton.<br />- Do not store above 30&deg;C.<br />- Do not throw away any medicines via wastewater<br />or household waste. Ask your pharmacist how to<br />throw away medicines you no longer use. These<br />measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is bromazepam.<br />- The other excipients are Microcrystalline<br />cellulose, lactose monohydrate, talc, magnesium<br />stearate, red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lexotanil tablets are supplied as:
3 mg tablets (scored; light red) 30, 100
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder<br />CHEPLAPHARM Arzneimittel GmbH<br />Ziegelhof 24<br />17489 Greifswald<br />Germany</p><p>Manufacturer<br />Delpharm Milano S.r.l.<br />Via Carnevale 1<br />20090 Segrate (MI)<br />Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><br />- شكل الدواء:<br />أقراص ليكسوتانيل ٣ ملغ: أقراص لونها أحمر فاتح قابلة للقطع ذات ٣ ملغ<br />من برومازيبام<br />- دواعي الاستعمال:<br />يستخدم ليكسوتانيل لعلاج الاضطرابات الانفعالية: حالات القلق والتوتر،<br />كدواء مساعد في حالة القلق عند الاكتئاب، التوتر العصبي، عدم الاستقرار<br />والأرق المرتبط بالقلق والتوتر.<br />كما يمكن أيضًا استخدام ليكسوتانيل لعلاج الاضطرابات الوظيفية أو النفسية-<br />الجسمية )سيكوسوماتية( في مختلف الأعضاء، والتي تحدث أو تتفاقم بسبب<br />القلق والتوتر، ويوصف عند الاقتضاء كعلاج تكميلي لمرض أساسي<br />&ndash; في الجهاز القلبي-الوعائي وفي جهاز التنفس )مثل الذبحة الصدرية الكاذبة،<br />القلق البركي )إحساس بالألم جهة الصدر أمام القلب(، تسرع القلب، ارتفاع<br />ضغط الشرايين بسب الانفعال، صعوبة التنفس، فرط التهوية(؛<br />&ndash; في الجهاز المعدي-المعوي )كعلاج إضافي لمتلازمة تهيج القولون، التهاب<br />القولون التقرحي، ألم شرسوفي، تشنج، تطبل البطن، إسهال، مثلا(؛<br />&ndash; في الجهاز التناسلي-البولي )تهيج المثانة، كثرة التبول، كعلاج إضافي مساعد في<br />حالة عسر الحيض، مثلا(؛<br />&ndash; اضطرابات نفسانية-جسمية أخرى )كعلاج إضافي مساعد في حالة الصداع<br />الراجع إلى عامل نفساني، الجلاد )مرض جلدي( الراجع إلى عامل نفساني.<br />ينفع ليكسوتانيل أيضا في معالجة حالات القلق والتوتر المرتبطة بمرض عضوي<br />مزمن؛ ويجدر استعماله أيضا كعلاج تكميلي للمعالجة النفسية في حالة<br />العصاب النفساني.<br />يتوجب عليك التحدث مع طبيبك في حال لم تشعر بتحسن أو ساءت حالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- موانع الاستعمال:<br />يحُظر استعمال ليكسوتانيل مع المرضى الذين يعانون من فرط الحساسية<br />تجاه البنزوديازيبينات، أو تجاه أحد السواغات. ولا ينبغي إعطاؤه للمرضى<br />المصابين بقصور شديد في وظيفة التنفس، أو بمتلازمة انقطاع النفس خلال<br />النوم، أو بالوهن العضلي، أو بقصور خطير في وظيفة الكبد )يمكن أن<br />تتسبب البنزوديازيبينات في زيادة حدة الاعتلال الدماغي الكبدي(. لا تعطى<br />البنزوديازيبينات للمرضى المدمنين أو الذين يشك في إدمانهم على تناول المواد<br />المثبطة للجهاز العصبي، بما فيها الكحول، أو مع المرضى الذين يعانون من<br />حساسية تجاه برومازيبام أو أي من المكونات الأخرى الموجودة في ليكسوتانيل.<br />يرجى الرجوع للقسم رقم 6 من هذه النشرة للاطلاع على القائمة الكاملة<br />للمكونات الموجودة في ليكسوتانيل.<br />أطلع مقدم الرعاية الصحية الخاص بك على جميع الأدوية التي تتعاطاها،<br />بما في ذلك الأدوية الوصفية، أو الأدوية التي تؤخذ دون وصفة طبية، أو<br />الفيتامينات، أو المكملات العشبية.<br />احتياطات عامة<br />الاستعمال المتزامن مع الكحول/مثبطات الجهاز العصبي المركزي<br />ينبغي تجنب استعمال ليكسوتانيل في نفس الوقت مع الكحول و/أو مثبطات<br />الجهاز العصبي المركزي. وذلك لأن هذا الاستعمال المتزامن يحتمل أن يقوي<br />التأثير السريري لليكسوتانيل، مع ما يمكن أن ينجم عنه من تسكين شديد<br />وانهيار تنفسي و/أو قلبي وعائي بالغ على المستوى السريري، وهو ما يمكن أن<br />يؤدي إلى الغيبوبة أو الوفاة )راجع &quot;التفاعلات الدوائية&quot; و&quot;الجرعة المفرطة&quot;(.<br />يجب استخدام ليكسوتانيل بحذر شديد مع لمرضى الذين سبق تشخيص<br />تعاطيهم المفرط للكحول أو المستحضرات الطبية أو العقارات الممنوعة.</p><p>90004638/10 SA-CP 86068141</p><p>التحمّل<br />إن استعمال ليكسوتانيل المتكرر لمدة طويلة يمكن أن يؤدي إلى انخفاض<br />الاستجابة نحو مفعول البنزوديازيبينات. بما أن أقراص ليكسوتانيل تحتوي<br />على اللاكتوز، فلا ينبغي للمرضى الذين يعانون المتلازمة الوراثية النادرة لعدم<br />تحمل الغالاكتوز، أو نقص اللاكتاز، أو سوء امتصاص الغلوكوز-غالاكتوز، أن<br />يستعملوا أقراص ليكسوتانيل.<br />القصور الكبدي<br />قد تساهم البنزوديازيبينات في حدوث نوبات الاعتلال الدماغي الكبدي؛<br />وذلك لدى مرضى القصور الكبدي الشديد )راجع &quot;موانع الاستعمال&quot;(. ويجب<br />اتخاذ احتياطات خاصة عند استخدام ليكسوتانيل مع المرضى الذين يعانون<br />من اضطرابات وظيفة الكبد التي تتراوح ما بين الخفيفة إلى المعتدلة.<br />ردود الفعل النفسية و&quot;التناقضية&quot;<br />التفاعلات التناقضية مثل الاضطراب، والاستثارة، والتهيج، والعدوانية، والقلق،<br />والهذيان، ونوبات الغضب، والكوابيس، والهلوسة، والذهان، أو السلوك<br />غير المناسب وغير ذلك من الاضطرابات السلوكية؛ هي آثار معروفة تكون<br />مصاحبة للعلاج باستخدام البنزوديازيبينات. ويجب إيقاف العلاج في حالة<br />حدوث مثل هذه التفاعلات. ومن المرجح أن تحدث مثل هذه التفاعلات لدى<br />الأطفال والمسنين، أكثر مما تحدث لدى المرضى الآخرين.<br />المرضى المسنون<br />يبدو أن التأثيرات الدوائية للبنزوديازيبينات تكون أكثر وضوحًا في المرضى<br />المسنين، مقارنة بالمرضى الأصغر سنًا؛ وذلك حتى في تركيزات البلازما المماثلة.<br />وقد يعود السبب في ذلك إلى التغيرات المرتبطة بالسن والخاصة بتفاعلات<br />العنصر المُسْتقَْبلِ /النشط، وآليات ما بعد المُسْتقَْبِل وكذلك عمل أجهزة<br />الجسم. وينصح بخفض جرعة الدواء؛ وذلك بالنسبة للمرضى الذين تزيد<br />أعمارهم عن 50 سنة.<br />تناول ليكساتونيل مع الطعام و الشراب و الكحول<br />أثناء العلاج بأقراص ليكساتونيل، تجنب المشروبات الكحولية. يجب ابتلاع<br />أقراص ليكساتونيل بالماء أو العصير</p><p>الحمل<br />لا ينبغي استعمال ليكسوتانيل خلال الحمل ما عدا إذا دعت الضرورة المطلقة<br />إلى استعماله ولم يكن هناك علاج آخر أضمن لسلامة المريض. إذا وُصف هذا<br />الدواء لامرأة في سن الإنجاب فينبغي تنبيهها إلى أهمية إعلام الطبيب بما<br />إذا كانت تتوقع أن تصبح حاملا أو تظن أنها حامل، إذ يجب في هذه الحالة<br />أن تتوقف عن العلاج. لم تثبت بعدُ سلامة استعمال برومازيبام لدى المرأة<br />الحامل.<br />الإرضاع<br />بما أن البنزوديازيبينات تمر إلى حليب الأم فينبغي على الأمهات المرضعات أن<br />لا يتناولن ليكسوتانيل، أو أن يتوقفن عن الإرضاع في حال لزوم تناول الدواء.<br />التأثير في القدرة على قيادة السيارات وتشغيل الآلات<br />إن مفعول ليكسوتانيل وتأثيراته الجانبية كلاهما قد يؤثر في قدرة المريض<br />على قيادة السيارات أو تشغيل الآلات أو القيام بأي نشاط آخر خطير. لذلك<br />ينبغي تجنب القيام بهذه الأنشطة خلال فترة العلاج أو على الأقل خلال الأيام<br />الأولى منه. إن القرار في هذا الشأن يجب أن يتخذه الطبيب المعالج في كل<br />حالة على حدة، بناء على تفاعل المريض وعلى قدر الجرعة المعطاة. يجب<br />كذلك تحذير المرضى من تناول الكحول أثناء خضوعهم للعلاج بليكسوتانيل،<br />فتناول هاتين المادتين معا قد يقوّي التأثيرات غير المستحبة لكل منهما.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول ليكسوتانيل بالطريقة التي أطلعك عليها مقدم الرعاية الصحية o<br />الخاص بك. لا تغير الجرعة الخاصة بك أو تتوقف عن تناوله إلا إذا أخبرك<br />موفر الرعاية الصحية بذلك.<br />الجرعة العادية<br />3 ملغ إلى حتى ثلاث مرات - معدل الجرعات في العلاج خارج المستشفى: 1.5<br />في اليوم.<br />12 ملغ مرتين إلى - في الحالات الخطيرة، خاصة في العلاج داخل المستشفى: 6<br />ثلاث مرات في اليوم.<br />إن الجرعات المذكورة أعلاه مطابقة للتوصيات العامة، وينبغي تكييفها حسب<br />كل حالة على حدة. إن العلاج خارج المستشفى ينبغي الشروع فيه بجرعات<br />ضعيفة، ثم ينبغي الزيادة فيها تدريجيا حتى يحُصل على أحسن تأثير للدواء.<br />فترة العلاج<br />وينبغي أن يستغرق العلاج أقصر مدة ممكنة. كما يجب إعادة تقييم حالة<br />المريض بعد فواصل منتظمة، وتقرير ما إذا كان يلزم متابعة العلاج أم لا،<br />خاصة عندما تختفي أعراض المرض. وينبغي عموما أن لا تتجاوز مدة العلاج<br />12-8 أسبوعا كمدة قصوى، بما في ذلك مرحلة التوقف التدريجي عن تناول<br />الدواء. قد يلزم في بعض الحالات أن يستمر العلاج أزيد من المدة القصوى<br />الموصي بها، ولكن ينبغي في هذه الحالات إعادة تقييم حالة المريض وداعي<br />الاستعمال بدقة وعناية.<br />يجب - في بداية العلاج- فحص المريض بانتظام من أجل الحفاظ على الجرعة</p><p>و / أو عدد مرات تناولها عند أدنى مستوى ممكن، وكذلك تجنب التعرض<br />لخطر الجرعة المفرطة نتيجة لتراكم الدواء في الجسم.<br />قد يكون من المفيد - عند بدء العلاج - إبلاغ المريض أن العلاج لن يستمر<br />إلا لفترة معينة، وأن الجرعة سوف تنخفض تدريجيًا في النهاية؛ كما أنه من<br />المهم إبلاغ المريض بإمكانية حدوث ظاهرة الارتداد، وكذلك الشعور بأعراض<br />الانسحاب )انسحاب الدواء( عند إيقاف العلاج.<br />إرشادات خاصة متعلقة بالجرعات<br />الاستخدام مع المرضى من الأطفال<br />ينبغي، كما هو الشأن مع باقي البنزوديازيبينات، أن لا يعطى ليكسوتانيل<br />للأطفال والمراهقين إلا بعد الموازنة الدقيقة بين فوائد العلاج ومخاطره. إذا<br />ارتأى الطبيب وصف ليكسوتانيل فينبغي أن تحدد جرعته حسب الوزن<br />الضعيف لجسم الطفل.<br />الاستخدام مع المرضى المسنين<br />من الضروري إعطاء جرعات أقل للمرضى المسنين؛ وذلك بسبب إمكانية<br />زيادة الحساسية لدى هذه الفئة من المرضى، وكذلك نتيجة لاختلاف الحرائك<br />الدوائية لدى هؤلاء المرضى.<br />الاستخدام مع مرضى القصور الكبدي<br />يجب ألا يعُالج المرضى الذين يعانون من القصور الكبدي الشديد باستخدام<br />أقراص ليكسوتانيل؛ كما يجب أن يحصل المرضى الذين يعانون من القصور<br />الكبدي الذي يتراوح ما بين البسيط إلى المتوسط، على أقل جرعة ممكنة.<br />فرط الجرعة<br />الأعراض<br />يؤدي فرط جرعة البنزوديازيبين غالبا إلى الذهول والرنح وعسر التلفظ<br />والرأرأة. بالرغم من أن فرط جرعة ليكسوتانيل نادرا ما يهدد حياة المريض<br />إذا تنوول المستحضر وحده، فإنه يمكن أن يسبب فقد المنعكسات، وانقطاع<br />النفس، وانخفاض الضغط، وانهيار القلب والتنفس، وغيبوبة )كوما(. إذا<br />وقعت الغيبوبة فإنها عموما تدوم ساعات قليلة فقط، لكن يمكن أحيانا<br />أن تطول وأن تحدث بشكل دوري، خصوصا لدى المرضى المسنين. إن انهيار<br />التنفس الذي تسببه البينزوديازيبينات يكون أكثر شدة في المرضى المصابين<br />بمرض تنفسي. تقوي البنزوديازيبينات مفعول الأدوية المثبطة للجهاز العصبي<br />المركزي، بما في ذلك الكحول.</p><p>العلاج<br />تجرى مراقبة الوظائف الحيوية للمريض ويشرع في تدابير الدعم التي تمليها<br />حالته السريرية. قد يحتاج المرضى، بوجه خاص، لعلاج أعراضي للتأثيرات<br />القلبية التنفسية أو التي تصيب الجهاز العصبي المركزي.<br />ينبغي قطع امتصاص الدواء بواسطة التدابير المناسبة، مثل العلاج بالفحم<br />2 ساعات من حدوث فرط الجرعة. - المفعل داخل 1<br />إذا أعطي الفحم المفعّل لمرضى وسنانين )يعانون النعاس( يجب أساسا الحفاظ<br />على نفوذية مسالك التهوية لديهم. إذا تناول المريض أكثر من دواء واحد<br />فيمكن التفكير في إجراء غسل المعدة، لكن ليس كإجراء روتيني.<br />ينبغي في حال المرضى الذين يعانون انهيارا بالغا في الجهاز العصبي المركزي<br />يجب، في .)&reg; التفكير في استعمال مضاد البنزوديازيبين فلومازينيل )أنيكسات<br />جميع الأحوال، أن يعطى هذا المستحضر تحت المراقبة الدقيقة كما يجب<br />أن يخضع المرضى، نظرا إلى قصر نصف عمر فلومازينيل، للمراقبة حينما<br />يزول تأثير الدواء. يجب توخي الحذر الشديد عند استعمال فلومازينيل بعد<br />تناول مواد مخفّضة لعتبة نوبة الاختلاج )مضادات الاكتئاب ثلاثية الأطوار،<br />مثلا(. وللمزيد من المعلومات حول طريقة الاستعمال الصحيحة لفلوماتزينيل<br />يرجى الرجوع إلى النشرة العلمية حول المستحضر. ،)&reg; )أنيكسات<br />نسيان تناول الجرعة<br />لا تقم بأخذ جرعة إضافية لتعويض الجرعة المنسية.<br />عند التوقف عن استخدام ليكسوتانيل<br />يقترن التوقف المفاجئ عن تناول العلاج بظهور أعراض الانسحاب؛ وذلك<br />بمجرد أن يتحقق الاعتماد الجسماني على الدواء.<br />وتشمل تلك الأعراض على وجه الخصوص الصداع، والإسهال، وألم العضلات،<br />والقلق الشديد، والتوتر، والأرق، والارتباك والتهيج؛ كما قد تحدث الأعراض<br />التالية في الحالات الشديدة:<br />عن الواقِع، وتبَدُّدُ الشَّخْصِيَّة، واحْتِدَادُ السَّمْع، والشعور بخدر ووخز في<br />الأطراف؛ بالإضافة إلى فرط الحساسية للضوء، والضوضاء والاتصال الجسدي؛<br />وكذلك الهلوسة أو نوبات الصرع.<br />عند استعمال البنزوديازيبينات، قد تحدث أعراض الانسحاب أيضًا عند<br />التبديل إلى استعمال البنزوديازيبين، حيث يكون العمُُرُ النِّصْفِيّ للإطراح<br />أقصر بكثير.<br />يمكن أن تظهر أعراض الحرمان بعد ساعات أو أسبوع أو حتى بعد مدة أطول<br />من التوقف عن استعمال الدواء، وذلك حسب مدة تأثير الدواء.<br />في حال كان لديك أية أسئلة إضافية حول استخدام هذا المنتج، اسأل طبيبك<br />أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب ليكسوتانيل آثارًا جانبية، إلا أنها قد لا<br />تصيب الجميع.<br />تجربة ما بعد تسويق المستحضر<br />إن التأثيرات غير المستحبة المتوقعة أكثر مع العلاج ببرومازيبام هي التالية:<br />تسكين، دوار، وسن، انخفاض الضغط، ضعف التركيز، إبطاء رد الفعل.<br />وردت حالات كثيرة من السقوط والكسر لدى مستعملي البينزوديازيبينات.<br />ويزيد احتمال هذه الوقائع لدى الذين يتلقون تزامنا المهدئات )بما في ذلك<br />المشروبات الكحولية( ولدى المسنين.<br />التأثيرات النفسية<br />الارتباك، والتوهان، والاضطرابات العاطفية والاضطرابات المزاجية. تحدث<br />هذه التأثيرات أساسا عند بداية العلاج وتختفي عموما مع متابعة استعمال<br />الدواء. يمكن أن يظهر على المريض خلال العلاج بالبنزوديازيبينات<br />مرض الاكتئاب الكامن )الموجود من قبل(. وتظهر عادة مع استعمال<br />البنزوديازيبينات أو المواد المشابهة لها تفاعلات مناقضة للمألوف، مثل عدم<br />الاستقرار، الاستثارة، الهيوجية )القابلية للتهيج(، العدوانية، الهذيان، نوبات<br />غضب، كوابيس، أهلاس، ذهان، سلوك غير ملائم، والعصبية، والقلق، والأحلام<br />غير الطبيعية وفرط النشاط بالإضافة إلى الآثار غير المستحبة الأخرى المعروفة<br />والمرتبطة بالسلوك. وتحدث ردود الفعل هذه بشكل أكثر في الأطفال وكبار<br />السن.<br />التأثيرات على الجهاز العصبي<br />كثيرا: تعب، وسن، صداع )ألم الرأس(، ضعف التركيز، دوار )دوخة(، إبطاء<br />رد الفعل.<br />نادرا: رنح )فقد التساند العضلي(، نسيان اللاحق.<br />تحدث هذه الاضطرابات أساسا في بداية العلاج وتزول عموما مع متابعة<br />الاستعمال.<br />من الممكن أن يحدث نسيان اللاحق )حيث كل ما يحدث بعد أخذ الدواء<br />)بساعات قليلة عادة( لا يستطيع المريض أن يتذكره فيما بعد( مع الجرعات<br />العلاجية، ويزيد احتماله مع زيادة الجرعة.<br />التأثيرات البصرية<br />ازدواج الرؤية. يحدث هذا العرض أساسا في بداية العلاج ويزول عموما مع<br />الاستمرار في العلاج.<br />التأثيرات على الأذن وعلى قوقعة الأذن<br />كثيرا: دوار<br />يحدث هذا الاضطراب أساسا في بداية العلاج ويزول عموما مع الاستمرار في<br />العلاج</p><p>التأثيرات القلبية<br />قصور وظيفة القلب، بما في ذلك توقف القلب.<br />التأثيرات التنفسية، الصدرية والمنصفية<br />انهيار التنفس<br />التأثيرات المعدية - المعوية<br />أحيانا: اضطرابات معدية-معوية.<br />نادرا: غثيان، جفاف الفم، زيادة شهية الطعام.<br />التأثيرات على الجلد وعلى النسيج تحت الجلد<br />أحيانا: تفاعلات جلدية<br />التأثيرات العضلية الهيكلية والنسيج الضام<br />اضطرابات عضلية-هيكلية<br />نادرا: ضعف عضلي.<br />التأثيرات على أعضاء التناسل وعلى الثدي<br />أحيانا: تغير الليبيدو )الشهوانية(.<br />الاعتماد<br />إن استعمال الدواء لمدة طويلة )ولو بالجرعات العلاجية( يمكن أن يؤدي<br />إلى اعتماد فيزيقي ونفسي )تعلق مستمر بالدواء(: من الممكن أن تظهر<br />أعراض الحرمان أو آثار الارتداد بعد التوقف عن العلاج )راجع &quot;تحذيرات<br />واحتياطات&quot;(. لقد كانت حالات إساءة استعمال البنزوديازيبينات أكثر شيوعًا<br />في حالة استخدام مواد فعالة متعددة.<br />إذا شعرت بأية آثار جانبية، أخبر طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك<br />أية أثار جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بليكسوتانيل بعيدًا عن مرأى وتناول الأطفال.&nbsp;<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة &ordm;<br />يشير تاريخ انتهاء الصلاحية هذا إلى آخر يوم من ذلك .)EXP( والكرتون<br />الشهر.<br />لا تخزنه في درجة حرارة أعلى من 30 درجة مئوية. &ordm;<br />لا يجب التخلص من الأدوية عبر مياه الصرف أو النفايات المنزلية. اسأل &ordm;<br />الصيدلي عن كيفية التخلص من الأدوية التي لم تعد في حاجة إليها، حيث<br />تساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة برومازيبام<br />المكونات غير الفعالة: سيليلوز دقيق التبلور، لاكتوز أحادي الإماهة، طلق،<br />ستيارات المغنيزوم، أوكسيد الحديد الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر كبسولات ليكسوتانيل على النحو التالي:<br />100 ،30أقراص ٣ ملغ (قابلة للقطع، لونها أحمر فاتح)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك رخصة التسويق<br />شيبلافارم أرزنايميتل ج م ب ه<br />زيجلهوف 24<br />17489 غرايفسفالد<br />ألمانيا<br />المصنع<br />دلفارم ميلانو ش.م.م<br />فيا كارنيفال 1<br />20090 ، سيجراتي(ام اي)<br />إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير ٢٠٢١ م.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lexotanil 3mg Tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient: bromazepam.
Excipients:
3 mg tablets: microcrystalline cellulose, lactose monohydrate, talc, magnesium stearate, red iron oxide
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                light-red scored tablet, 3 mg bromazepam
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lexotanil is used for the treatment of emotional disorders: anxiety and tension states, as adjuvant therapy for anxiety in depression, nervous tension, restlessness, and anxiety- and tension-related insomnia.<br />Lexotanil can also be used for the treatment of functional or psychosomatic impairments of various organs caused or exacerbated by anxiety and tension, and possibly as an adjuvant to treatment of underlying disease of the<br />&minus; cardiovascular and respiratory systems (e.g. pseudoangina, precordial anxiety, tachycardia, hypertension of emotional origin, dyspnea, hyperventilation);<br />&minus; gastrointestinal tract (e.g. adjuvant treatment of irritable bowel syndrome, ulcerative colitis, epigastric pain, spasm, abdominal distension, diarrhea);<br />&minus; urogenital system (e.g. irritable bladder, urinary frequency, adjuvant treatment of dysmenorrhea);<br />&minus; other psychosomatic disorders (e.g. adjuvant treatment of psychogenic headache, psychogenic dermatoses).<br />Lexotanil is also suitable for treatment of anxiety and tension states due to chronic organic disease and as an adjuvant to psychotherapy in psychoneuroses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Standard dosage<br />Average dose for outpatient treatment: 1.5 &ndash; 3 mg up to three times daily.<br />In severe cases, especially for inpatients: 6 &ndash; 12 mg two to three times daily.<br />The doses indicated represent general guidelines and must be individually tailored in each case. Treatment of outpatients should begin with low doses, which should be gradually titrated to the optimum level.<br />Duration of treatment<br />The duration of treatment should be as short as possible. The patient&rsquo;s condition should be reassessed at regular intervals and the need for continuation of treatment determined, especially when the patient&rsquo;s symptoms have resolved. As a general rule, the total duration of treatment should not exceed 8 &ndash; 12 weeks, including a tapering-off period. In certain cases, treatment may need to be continued beyond the maximum recommended duration, but only after careful reassessment of the patient&rsquo;s condition and the indication.<br />Patients should be examined regularly at the start of treatment in order to minimize the dose and/or frequency of administration and to avoid the risk of overdose of the product due to accumulation.<br />At the outset it may be useful to inform the patient that the duration of treatment will be for a limited time only and that the dose will be gradually reduced at the end of the treatment period. It is important for the patient to be aware that rebound effects and withdrawal symptoms may occur when treatment is discontinued.<br />Special dosage instructions Use in pediatric patients<br />As with other benzodiazepines, Lexotanil should only be given to children and adolescents after careful consideration of the relative risks and benefits. If treatment with Lexotanil is considered by a doctor to be indicated, the dose should be adjusted to the child&rsquo;s lower body weight.<br />Use in elderly patients<br />Elderly patients require lower doses due to potentially increased sensitivity and different pharmacokinetics.<br />Impaired hepatic function<br />Patients with severe hepatic impairment should not be treated with Lexotanil tablets. Patients with mild or moderate hepatic impairment should receive the lowest possible dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lexotanil is contraindicated in patients with hypersensitivity to benzodiazepines or any of the excipients, severe respiratory insufficiency, sleep apnea syndrome, myasthenia gravis or severe hepatic impairment (benzodiazepines may exacerbate hepatic encephalopathy).
Patients known or suspected to be dependent on CNS depressants, including alcohol, must not take benzodiazepines.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caution should be exercised in patients with chronic respiratory insufficiency, in view of the risk of respiratory depression.<br />Benzodiazepines are not suitable for the primary treatment of a psychotic disorder.<br />Benzodiazepines should not be used alone to treat depression or anxiety states associated with depression.<br />Amnesia<br />Benzodiazepines can cause anterograde amnesia. This means that things may happen (usually a few hours) after taking the medication that the patient cannot later remember. This risk increases with the dose.<br />Dependence<br />The use of benzodiazepines may cause physical and psychological dependence. This risk is increased with prolonged use, at high dosages and in predisposed patients in whom abuse of alcohol, medicinal products, or illegal drugs has previously been diagnosed. Abuse of the medicinal product has been reported more frequently in cases of multiple substance use.<br />Withdrawal<br />Once physical dependence has developed, discontinuation of treatment will be accompanied by withdrawal symptoms. These may comprise headache, diarrhea, muscle pain, extreme anxiety, tension, restlessness, confusion and irritability. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of extremities, hypersensitivity to light, noise and physical contact, hallucinations or convulsions.<br />Withdrawal symptoms may also occur when switching from one benzodiazepine to another drug in the same class with a substantially shorter elimination half-life.<br />Depending on the duration of action of the substance, the onset of withdrawal symptoms can vary from a few hours to a week or more after discontinuation of treatment.<br />To keep the risk of dependence to a minimum, benzodiazepines should be prescribed only after careful assessment of the indication and should be used for the shortest possible period (e.g. as a hypnotic they should not generally be used for longer than 4 weeks). The need for continued treatment must be reviewed periodically. Longer-term treatment is only indicated in certain patients (e.g. for panic attacks), the benefits being less clear in relation to the risks.<br />Rebound phenomenon<br />Rebound phenomenon is a transient syndrome in which the symptoms that led to treatment with Lexotanil occur in more severe form on withdrawal of treatment. It may be accompanied by other reactions including mood changes, anxiety or sleep disturbances and restlessness.</p><p>To prevent withdrawal symptoms or rebound phenomena, tapering off is recommended as the standard method of discontinuation, i.e. the dose should be gradually reduced. Should withdrawal symptoms or rebound phenomena occur, the patient will require close medical supervision and support.<br />General precautions<br />Concomitant use of alcohol/CNS depressants<br />The concomitant use of Lexotanil with alcohol and/or CNS depressants should be avoided. Such concomitant use can potentially intensify the clinical action of Lexotanil, possibly with heavy sedation and clinically relevant respiratory and/or cardiovascular depression, which may result in coma or death (see Interactions and Overdose).<br />Lexotanil should be used with extreme caution by patients in whom abuse of alcohol, medicinal products, or illegal drugs has previously been diagnosed.<br />Tolerance<br />Repeated use of Lexotanil for long periods can lead to a reduction in the response to the action of benzodiazepines.<br />Lexotanil tablets contain lactose. Patients with rare hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take Lexotanil tablets.<br />Impaired hepatic function<br />Benzodiazepines may play a contributory role in precipitating episodes of hepatic encephalopathy in patients with severe hepatic impairment (see &ldquo;Contraindications&rdquo;). Particular caution is required when administering Lexotanil to patients with mild to moderate hepatic impairment.<br />Psychiatric and &ldquo;paradoxical&rdquo; reactions<br />Paradoxical reactions such as restlessness, agitation, irritability, aggressiveness, anxiety, delusion, fits of rage, nightmares, hallucinations, psychosis, inappropriate behavior and other adverse behavioral effects are known to occur with the use of benzodiazepines. If such reactions occur, use of the drug should be discontinued. They are more likely to occur in children and elderly patients than in other patients.<br />Elderly patients<br />The pharmacological effects of benzodiazepines appear to be greater in elderly patients than in younger patients, even at similar plasma concentrations, possibly because of age-related changes in drug-receptor interactions, post-receptor mechanisms and organ function. Dose reduction is recommended in patients over 50 years old.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic drug-drug interaction (DDI)<br />Increased adverse reactions such as sedation and cardiorespiratory depression may occur when bromazepam is used in combination with CNS depressants, including alcohol.<br />Alcohol should be avoided by patients taking bromazepam (see also General precautions). Advice on other CNS depressants, including alcohol, is also given under Overdose.<br />In the case of narcotic analgesics intensification of euphoria can occur, which can lead to increased dependence.<br />In patients receiving muscle relaxants, the increased risk of muscular weakness should be borne in mind.<br />There is an increased risk of respiratory depression.<br />Pharmacokinetic drug-drug interaction (DDI)<br />There is a possibility that compounds which inhibit key oxidative hepatic enzymes may enhance the activity of benzodiazepines. Coadministration of cimetidine, an inhibitor of several CYP enzymes, and possibly propranolol may prolong the elimination half-life of bromazepam through a substantially reduced clearance (with cimetidine: reduction by 50%). Combined administration with fluvoxamine, an inhibitor of CYP1A2, results in significantly increased bromazepam exposure (2.4-fold higher AUC) and elimination half-life (1.9-fold higher).<br />Bromazepam had no effect on phenazone metabolism, a surrogate marker for CYP1A2, CYP2B6,<br />CYP2C and CYP3A activity. Moreover, bromazepam did not induce major CYP450 isozymes in vitro at the level of mRNA; nor did it activate nuclear hormone receptors. Therefore, bromazepam is unlikely to cause pharmacokinetic drug-drug interactions based on CYP450 induction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lexotanil should not be used during pregnancy unless it is clearly necessary and there is no safer alternative available.<br />If the drug is prescribed to a woman of child-bearing age, she should be advised to tell her doctor if she plans to become or suspects that she is pregnant, so that treatment may be discontinued.<br />The safety of bromazepam in pregnant women has not been established. There is no evidence from spontaneously reported adverse drug reactions that the incidence is any higher than would be expected in a similar, untreated group of patients. Several studies have reported an increased risk of congenital malformations when tranquillizers (diazepam, meprobamate or chlordiazepoxide) are taken during the first trimester of pregnancy.<br />In humans, the risk of malformation associated with the use of therapeutic doses of benzodiazepines in early pregnancy appears to be low, although some epidemiological studies have pointed to an increased risk of cleft palate. There are case reports of malformations and mental retardation in children exposed prenatally after overdose and intoxication.</p><p>Use of bromazepam during the last trimester of pregnancy or during labour is allowed only if the clinical indication has been rigorously established, as the pharmacological action of the product means that effects on the neonate such as hypothermia, hypotonia and moderate respiratory depression can be expected.<br />Moreover, infants born to mothers who took benzodiazepines regularly during the later stages of pregnancy may have developed physical dependence and may therefore be at risk of developing withdrawal symptoms in the postnatal period.<br />Lactation<br />As benzodiazepines pass into breast milk, Lexotanil should not be taken by nursing mothers or else breastfeeding should be discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As a consequence of the action and possible side effects of the drug, the ability to drive, operate machinery or undertake any other hazardous activities may be impaired. Patients should therefore abstain from such activities entirely or at the very least for the first few days of treatment. The decision in each individual case must be made by the doctor in charge of the patient&rsquo;s treatment on the basis of individual reaction and the administered dose. The patient must also be warned to abstain from alcohol while on the drug, as this combination can potentiate the undesirable effects of both substances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Post-marketing experience<br />During treatment with bromazepam, the following adverse effects can be expected to occur with the greatest frequency: sedation, dizziness, drowsiness, hypotension, poor concentration and slow reactions. There have been frequent reports of falls and fractures in benzodiazepine users. The risk is increased in those taking concomitant sedatives (including alcoholic beverages) and in the elderly.<br />Psychiatric disorders<br />Confusional state, disorientation, emotional and mood disturbances. These effects occur primarily at the start of treatment and generally disappear with continued use.<br />Pre-existing depression may be unmasked during treatment with benzodiazepines.<br />Paradoxical reactions such as restlessness, agitation, irritability, aggressiveness, delusion, fits of rage, nightmares, hallucinations, psychosis, inappropriate behavior, nervousness, anxiety, abnormal dreams, hyperactivity and other adverse behavioral effects are known to occur. Such reactions are more common in children and elderly patients than in other patients.<br />Nervous system disorders<br />Common: Fatigue, drowsiness, headache, poor concentration, dizziness, slow reactions.<br />Rare: Ataxia, anterograde amnesia.<br />These effects occur primarily at the start of treatment and generally disappear with continued use.<br />Anterograde amnesia may occur at therapeutic doses, with the risk increasing at higher doses. This means that things may happen (usually a few hours) after taking the medication that the patient cannot later remember.</p><p>Eye disorders<br />Double vision<br />This effect occurs primarily at the start of treatment and generally disappears with continued use.<br />Ear and labyrinth disorders<br />Common: Dizziness<br />This effect occurs primarily at the start of treatment and generally disappears with continued use.<br />Cardiac disorders<br />Heart failure, including cardiac arrest.<br />Respiratory, thoracic and mediastinal disorders<br />Respiratory depression.<br />Gastrointestinal disorders<br />Uncommon: Gastrointestinal disturbances<br />Rare: Nausea, dry mouth, increased appetite.<br />Skin and subcutaneous tissue disorders<br />Uncommon: Dermatological reactions<br />Musculoskeletal and connective tissue disorders<br />Rare: Muscle weakness<br />This effect occurs primarily at the start of treatment and generally disappears with continued use.<br />Reproductive system and breast disorders<br />Uncommon: Changes in libido<br />Dependence<br />Long-term use (even at therapeutic doses) can lead to physical and psychological dependence: withdrawal symptoms or rebound effects may occur when the drug is discontinued (see Warnings and precautions). Abuse of benzodiazepines is more common in multiple substance use.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />&minus; The National Pharmacovigilance Centre (NPC)<br />&bull; SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/</p><p>&bull; Other GCC States:</p><p>&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Overdosage with benzodiazepines commonly leads to stupor, ataxia, dysarthria, and nystagmus.<br />Although overdosage with Lexotanil is rarely life-threatening when the product has been taken on its own, it can lead to areflexia, apnea, hypotension, cardiorespiratory depression, and coma. If coma develops, it generally lasts only a few hours, but can sometimes be protracted and cyclic, particularly in the elderly. Respiratory depression caused by benzodiazepines is more severe in patients with respiratory illnesses.<br />Benzodiazepines potentiate the effects of other CNS depressants, including alcohol.<br />Treatment<br />Monitor the patient&rsquo;s vital functions and instigate whatever supportive measures are indicated by his/her clinical state. Patients may, in particular, require symptomatic treatment of cardiorespiratory or CNS effects.<br />Further absorption should be prevented by appropriate means, e.g. by treatment with activated charcoal within 1&ndash;2 h. In drowsy patients, airway protection is essential if activated charcoal is administered. If more than one substance has been ingested, gastric lavage may be considered, but is not a routine countermeasure.<br />In patients with serious CNS depression, administration of the benzodiazepine antagonist flumazenil (Anexate&reg;) should be considered. This product must, however, be administered under close supervision and, because it only has a short half-life (about one hour), patients administered flumazenil must be kept under supervision once its effects have worn off. Flumazenil must be used with extreme caution after ingestion of substances that lower the seizure threshold (e.g. tricyclic antidepressants). For further information on the correct use of flumazenil (Anexate&reg;), refer to the prescribing information for the product.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: benzodiazepines (GABA receptor inhibitor), ATC code: N05BA08.<br />Mechanism of action/pharmacodynamics<br />The central effect of benzodiazepines is mediated by potentiation of GABAergic neurotransmission at inhibitory synapses. In the presence of benzodiazepines, the affinity of the GABA receptor for the neurotransmitter is increased by positive allosteric modulation, resulting in an enhanced effect of released GABA on chloride ion influx through the postsynaptic membrane.<br />At low doses, Lexotanil relieves anxiety, tension and nervousness. At high doses, it has sedative and muscle relaxant effects.</p><p>Clinical efficacy<br />Clinical efficacy has been demonstrated in various clinical studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />After oral administration of bromazepam, peak plasma concentrations are reached within 2 h. The absolute bioavailability from the tablet (relative to the i.v. solution) is 60%. Food may decrease the bioavailability of bromazepam, although it has not been demonstrated that this is clinically relevant. The degree of absorption remains constant after ingestion of multiple bromazepam doses; steady-state concentrations are calculable and confirm the linear kinetics of the active substance. Steady-state plasma concentrations are reached in about five to nine days. Following multiple oral doses of 3 mg three times daily, the average maximum steady-state concentration of bromazepam was 120 ng/ml, which is three- to four-fold higher than that observed after a single 3 mg dose.<br />Distribution<br />Bromazepam is rapidly distributed in the body after absorption. On average, 70% of bromazepam is bound to plasma proteins by hydrophobic interaction; binding partners are albumin and &alpha;1-acid glycoprotein. The volume of distribution is about 50 litres.<br />Metabolism<br />Bromazepam is extensively metabolized in the liver. No metabolites are formed that have a longer half-life than the parent compound. Quantitatively, two metabolites predominate: 3-hydroxybromazepam (less active than bromazepam) and 2-(2-amino-5-bromo-3- hydroxybenzoyl)-pyridine (inactive).<br />Bromazepam is metabolized, at least in part, through cytochrome P450 (CYP450). However, it is still unclear exactly which CYP isozymes are involved in this process. Nevertheless, the observations that a strong CYP3A4 inhibitor (itraconazole) and a moderate CYP2C9 inhibitor (fluconazole) have no effect on the pharmacokinetics of bromazepam suggest that these isozymes are not involved to a major extent. However, the pronounced interaction with fluvoxamine (see Interactions) points to involvement of CYP1A2.<br />Elimination<br />Bromazepam has an elimination half-life of about 20 hours and an elimination clearance of about 40 ml/min.<br />The drug is mainly eliminated by metabolism. Only about 2% of bromazepam is excreted unchanged in the urine, while the glucuronide conjugates of 3-hydroxybromazepam and 2-(2- amino-5-bromo-3-hydroxybenzoyl)-pyridine account, respectively, for 27% and 40% of the administered dose.<br />Pharmacokinetics in special populations<br />Elderly patients<br />Elderly patients may have significantly higher peak concentrations, a smaller volume of distribution, a greater unbound serum fraction, lower clearance and hence also a prolonged&nbsp;elimination half-life. This indicates that steady-state concentrations of bromazepam at any dosing rate will be on average nearly twice as high in elderly patients as in younger patients (see Dosage and administration, Special dosage instructions).<br />Impaired renal function<br />No special pharmacokinetic study has been conducted and no population pharmacokinetic data have been collected in patients with renal impairment.<br />Impaired hepatic function<br />No special pharmacokinetic study has been conducted and no population pharmacokinetic data have been collected in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenicity<br />Carcinogenicity studies in rats have not brought to light evidence of any carcinogenic potential for bromazepam.<br />Genotoxicity<br />In-vitro and in-vivo tests have not brought to light evidence of any mutagenic potential for bromazepam.<br />Impairment of fertility<br />Daily oral administration of bromazepam in rats had no effect on the animals&rsquo; fertility and general reproductive ability.<br />Reproductive toxicity<br />An increase in fetal mortality and in the number of stillbirths and a reduction in the survival rate of the offspring was observed after administration of bromazepam to pregnant rats. In embryotoxicity/teratogenicity studies, no teratogenic effects were observed at dosages of up to 125 mg/kg/day.<br />After oral doses of up to 50 mg/kg/day in pregnant rabbits, reduced maternal weight gain, lower fetal weight, and increased occurrence of fetal reabsorption were observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>microcrystalline cellulose, lactose monohydrate, talc, magnesium stearate, red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                60 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Keep out of reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC blister, contains 100 of 30mg tablet.3 mg tablets (scored; light red) 30, 100<br />*Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2021.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>